Gilead Sciences, Inc. (GILD): Price and Financial Metrics
Gilead Sciences, Inc. (GILD)
Today's Latest Price: $58.15 USD
Updated Oct 30 4:00pm
Add GILD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GILD Stock Summary
- GILD has a market capitalization of $73,380,487,376 -- more than approximately 97.46% of US stocks.
- With a one year PEG ratio of 299.24, Gilead Sciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 88.95% of US stocks.
- In terms of volatility of its share price, GILD is more volatile than merely 4.7% of stocks we're observing.
- Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are ATVI, ADI, AMAT, BIIB, and RACE.
- GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to www.gilead.com.
GILD Stock Price Chart Interactive Chart >
GILD Price/Volume Stats
| Current price | $58.15 | 52-week high | $85.97 |
| Prev. close | $58.53 | 52-week low | $57.04 |
| Day low | $57.18 | Volume | 11,871,600 |
| Day high | $58.58 | Avg. volume | 14,659,157 |
| 50-day MA | $63.48 | Dividend yield | 4.65% |
| 200-day MA | $70.97 | Market Cap | 72.90B |
Gilead Sciences, Inc. (GILD) Company Bio
Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
GILD Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $58.15 | $30.44 | -48% |
We started the process of determining a valid price forecast for Gilead Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Gilead Sciences Inc ranked in the 30th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Gilead Sciences Inc ended up being:
- The company's compound free cash flow growth rate over the past 5.45 years comes in at -0.06%; that's greater than just 17.52% of US stocks we're applying DCF forecasting to.
- The company has produced more trailing twelve month cash flow than 93.86% of its sector Healthcare.
- Gilead Sciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -49% |
| 1% | -49% |
| 2% | -48% |
| 3% | -48% |
| 4% | -47% |
| 5% | -47% |
HAPP, JNJ, QDEL, CPIX, and ILMN can be thought of as valuation peers to GILD, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...